MFT
FNCH

Moisand Fitzgerald Tamayo’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3
Closed -$11 – 665
2023
Q4 		$11 Hold
3
– – ﹤0.01% 651
2023
Q3 		$16 Buy
+3
New +$22 ﹤0.01% 761

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Moisand Fitzgerald Tamayo's FNCH Position: Q1 2024 in Review

Moisand Fitzgerald Tamayo sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2024, closing a stake of 3 shares — an estimated $11 sold.

Moisand Fitzgerald Tamayo first reported a position in FNCH in Q3 2023 and held it in 2 quarters. The position peaked at $16 in Q3 2023. 11 funds tracked by Wall St. Rank hold FNCH as of Q1 2024.

  • Moisand Fitzgerald Tamayo reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 3 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2024, an estimated $11.
  • Moisand Fitzgerald Tamayo first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Moisand Fitzgerald Tamayo's Finch Therapeutics Group, Inc. Common Stock position peaked at $16 in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2024.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q1 2024, filed 16 Apr 2024.